ADC Therapeutics Reports 88.7% ORR in LOTIS-7 and Preliminary Q3 Revenue of $21M
ADCT has more than doubled off its 52-week low of $0.78 on elevated volume (2.6× avg).
Summary
ADC Therapeutics released updated ASH abstracts showing 88.7% ORR and 75.3% CR for ZYNLONTA plus glofitamab in LOTIS-7, alongside full LOTIS-5 Phase 3 results that met the PFS endpoint but showed a Grade 5 safety imbalance. Preliminary Q3 revenue was $21M with $189.2M of cash as of September 30, 2026.
Key Events · Product Development and Regulatory · ADCT
-
LOTIS-7 Shows 88.7% ORR, 75.3% CR
Across 97 efficacy-evaluable r/r LBCL patients at the ZYNLONTA 150 µg/kg starting dose plus glofitamab, ORR was 88.7% and CRR 75.3%; 84.9% of complete responders remained in CR at the June 15, 2026 cutoff.
-
MZL IIT: 93% ORR, 90.8% Two-Year PFS
The Phase 2 investigator-initiated marginal zone lymphoma trial showed 93% ORR and 74.4% CRR among 43 efficacy-evaluable patients, with a two-year PFS rate of 90.8% at a median 23.2 months of follow-up.
-
LOTIS-5 Meets PFS But Grade 5 Imbalance
Median PFS was 6.14 vs 4.73 months (HR 0.73; P=0.0083), but Grade 5 TEAEs were 13.2% vs 4.6%, driven by infection-related events; the company says the FDA cited benefit-risk concerns and will update on regulatory strategy later.
-
Preliminary Q3 Revenue $21M, Cash $189.2M
Net product revenue from ZYNLONTA is expected at $21M for Q3 2026 versus $16M a year earlier, with cash of $189.2M at September 30, 2026 and $196M pro forma after the October refinancing; runway is expected into 2029.
Analysis · ADCT · Life Sciences
The LOTIS-7 combination data (88.7% ORR, 75.3% CR, responses still deepening at a median 10.35 months of follow-up) is the strongest efficacy readout in the ZYNLONTA program and the basis for a planned Phase 3 in 2L+ DLBCL, with compendia submission planned for Q1 2027. Against that, the full LOTIS-5 Phase 3 results show the confirmatory trial met its PFS endpoint (6.14 vs 4.73 months, HR 0.73) but carried a Grade 5 safety imbalance of 13.2% vs 4.6%, and the company notes the FDA cited benefit-risk concerns — so the accelerated approval path remains unresolved. Preliminary Q3 net product revenue of $21M and $189.2M of cash (about $196M pro forma for the October PIF refinancing) support a runway into 2029, which buys time for the regulatory strategy to play out.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADCT was trading at $1.72 on NYSE in the Life Sciences sector, with a market capitalization of approximately $219.6M. The 52-week trading range was $0.78 to $4.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.